Do analysts prefer ELYM or TSHA?

Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 160.07%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Taysha Gene Therapies 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.00

Is ELYM or TSHA more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Taysha Gene Therapies N/A -56.19% -41.84%

Do analysts recommend IMCR or ELYM?

Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 78.74%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts clearly believe Immunocore is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.58 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend FBRX or ELYM?

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.91%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, FBRX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is FBRX or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts recommend ELYM or ANAB?

AnaptysBio has a consensus price target of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AnaptysBio 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.69

Do analysts rate ELYM or SNDX?

Syndax Pharmaceuticals has a consensus price target of $42.30, indicating a potential upside of 139.80%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Syndax Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82

Eliem Therapeutics (ELYM) Competitors

$14.21 +0.57 (+4.18%)

As of 09/22/2026

Compare

ELYM vs. TSHA, IMCR, FBRX, ANAB, and SNDX

Should you buy Eliem Therapeutics stock or one of its competitors? Eliem Therapeutics's main competitors and comparable companies include Taysha Gene Therapies (TSHA), Immunocore (IMCR), Forte Biosciences (FBRX), AnaptysBio (ANAB), and Syndax Pharmaceuticals (SNDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Eliem Therapeutics (NASDAQ:ELYM) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 160.07%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Eliem Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Taysha Gene Therapies	$5.49M	291.68	-$109M	-$0.42	N/A

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics' return on equity of -47.03% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Taysha Gene Therapies and 0 mentions for Eliem Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.40 beat Eliem Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Taysha Gene Therapies	Neutral

Summary

Taysha Gene Therapies beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Eliem Therapeutics has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	3.77	-$35.51M	-$0.37	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market.

In the previous week, Immunocore had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Immunocore and 0 mentions for Eliem Therapeutics. Immunocore's average media sentiment score of 0.59 beat Eliem Therapeutics' score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Overall Sentiment
Immunocore	Positive
Eliem Therapeutics	Neutral

Eliem Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 78.74%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts clearly believe Immunocore is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

84.5% of Immunocore shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunocore beats Eliem Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.91%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Forte Biosciences' average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
Forte Biosciences	Neutral
Eliem Therapeutics	Neutral

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eliem Therapeutics' return on equity of -47.03% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Forte Biosciences has a beta of 2.62, meaning that its share price is 162% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

Summary

Forte Biosciences beats Eliem Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Eliem Therapeutics compare to AnaptysBio?

Eliem Therapeutics (NASDAQ:ELYM) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, AnaptysBio had 18 more articles in the media than Eliem Therapeutics. MarketBeat recorded 18 mentions for AnaptysBio and 0 mentions for Eliem Therapeutics. AnaptysBio's average media sentiment score of 0.52 beat Eliem Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
AnaptysBio	Positive

AnaptysBio has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45

AnaptysBio has a net margin of 82.37% compared to Eliem Therapeutics' net margin of 0.00%. AnaptysBio's return on equity of 112.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
AnaptysBio	82.37%	112.00%	2.20%

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 31.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AnaptysBio has a consensus price target of $79.15, suggesting a potential upside of 55.91%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

AnaptysBio beats Eliem Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Syndax Pharmaceuticals?

Eliem Therapeutics (NASDAQ:ELYM) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Eliem Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Syndax Pharmaceuticals	$172.35M	9.07	-$285.42M	-$2.51	N/A

Eliem Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Eliem Therapeutics' return on equity of -47.03% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Syndax Pharmaceuticals has a consensus price target of $42.30, indicating a potential upside of 139.80%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Syndax Pharmaceuticals and 0 mentions for Eliem Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.18 beat Eliem Therapeutics' score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Syndax Pharmaceuticals	Positive

Summary

Syndax Pharmaceuticals beats Eliem Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$422.78M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-26.81	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.64	15.40	10.47	6.32
Net Income	-$35.12M	-$22.82M	$3.49B	$359.73M
7 Day Performance	0.71%	-1.70%	-0.67%	0.17%
1 Month Performance	-17.77%	-6.17%	-3.17%	-3.27%
1 Year Performance	531.56%	30.67%	15.14%	5.58%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$14.21 +4.2%	N/A	+515.2%	$422.78M	N/A	N/A	9
TSHA Taysha Gene Therapies	2.915 of 5 stars	$5.07 +0.2%	$12.77 +151.9%	+68.2%	$1.65B	$9.77M	N/A	99	Positive News Analyst Forecast
IMCR Immunocore	3.451 of 5 stars	$31.59 -0.6%	$56.38 +78.5%	-8.4%	$1.64B	$400.02M	N/A	524
FBRX Forte Biosciences	0.9866 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
ANAB AnaptysBio	3.4539 of 5 stars	$54.31 -0.7%	$79.85 +47.0%	+142.3%	$1.62B	$234.60M	N/A	104	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. TSHA, IMCR, FBRX, ANAB, and SNDX

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Summary

How does Eliem Therapeutics compare to Immunocore?

Summary

How does Eliem Therapeutics compare to Forte Biosciences?

Summary

How does Eliem Therapeutics compare to AnaptysBio?

Summary

How does Eliem Therapeutics compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. TSHA, IMCR, FBRX, ANAB, and SNDX

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Do analysts prefer ELYM or TSHA?

Which has better earnings & valuation, ELYM or TSHA?

Which has more risk & volatility, ELYM or TSHA?

Do institutionals & insiders believe in ELYM or TSHA?

Is ELYM or TSHA more profitable?

Does the media prefer ELYM or TSHA?

Summary

How does Eliem Therapeutics compare to Immunocore?

Which has better valuation & earnings, IMCR or ELYM?

Which has more risk and volatility, IMCR or ELYM?

Does the media favor IMCR or ELYM?

Is IMCR or ELYM more profitable?

Do analysts recommend IMCR or ELYM?

Do institutionals & insiders believe in IMCR or ELYM?

Summary

How does Eliem Therapeutics compare to Forte Biosciences?

Do analysts recommend FBRX or ELYM?

Does the media refer more to FBRX or ELYM?

Do institutionals and insiders believe in FBRX or ELYM?

Is FBRX or ELYM more profitable?

Which has better earnings & valuation, FBRX or ELYM?

Which has more volatility & risk, FBRX or ELYM?

Summary

How does Eliem Therapeutics compare to AnaptysBio?

Does the media favor ELYM or ANAB?

Which has better valuation and earnings, ELYM or ANAB?

Is ELYM or ANAB more profitable?

Which has more risk & volatility, ELYM or ANAB?

Do insiders & institutionals have more ownership in ELYM or ANAB?

Do analysts recommend ELYM or ANAB?

Summary

How does Eliem Therapeutics compare to Syndax Pharmaceuticals?

Which has higher earnings and valuation, ELYM or SNDX?

Is ELYM or SNDX more profitable?

Do analysts rate ELYM or SNDX?

Which has more risk & volatility, ELYM or SNDX?

Do insiders & institutionals have more ownership in ELYM or SNDX?

Does the media prefer ELYM or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools